Galmed Pharmaceuticals Ltd.
GLMDNasdaq
$0.55
↓ -0.8%Jul 17 close · end-of-day
Price
1Y↓ -75.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.4M
Enterprise Value
-$8.6M
P/E
—
P/S
—
P/B
0.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$10.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-65.3%
ROIC
—
Debt / Equity
—
Net Cash
$11.0M
Return 1Y
-76.6%
Company profile
Galmed Pharmaceuticals Ltd. develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.
- CEO
- Allen Baharaff
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Website
- galmedpharma.com
Earnings
GLMD Q4 2025 Earnings
Period ends 2025-12-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$30.2M | — | — | — | — | — |
| Net income | -$28.8M | -$32.5M | -$17.9M | -$6.9M | -$7.5M | -$10.3M |
| Diluted EPS | — | $19.80 | $127.80 | $30.00 | $8.08 | $2.39 |
| Operating cash flow | -$26.3M | -$32.9M | -$18.5M | -$6.1M | -$5.9M | -$6.3M |
| Free cash flow | -$26.3M | -$32.9M | -$18.5M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q2 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$1.3M | -$1.1M | -$1.9M | -$3.2M | -$1.1M | -$2.5M | -$1.9M | -$4.8M |
| Diluted EPS | — | $1.65 | $2.31 | — | — | $0.63 | $0.33 | — |
| Operating cash flow | — | — | -$1.1M | — | — | — | -$1.9M | — |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.